Trial
NCT05130255
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Y-mAbs Therapeutics
Collaborators
—
Condition
SCLC
Intervention
GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)
Why stopped
Decision by Sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18